Lupin Limited (Lupin) announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 25 mg of Astellas Pharma Global Development Inc. Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of USD 1,019 million in the U.S. (IQVIA MAT February 2024).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,605 INR | +1.06% | -0.60% | +21.39% |
30/05 | India's pharma export sales to grow faster this year, trade body says | RE |
27/05 | Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.39% | 8.67B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
+9.78% | 210B | |
-5.52% | 206B | |
+6.17% | 164B |
- Stock Market
- Equities
- LUPIN Stock
- News Lupin Limited
- Lupin Limited Announces Launch of Mirabegron Extended-Release Tablets, 25 Mg, in the United States, After Having Received an Approval from the United States Food and Drug Administration